Generic Name and Formulations:
Brinzolamide 1%; oph. susp; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for AZOPT:
Open-angle glaucoma. Ocular hypertension.
1 drop 3 times daily.
Hepatic impairment. Severe renal impairment (CrCl <30mL/min): not recommended. Discontinue if serious systemic, ocular (eg, conjunctivitis, lid edema), or hypersensitivity reactions occur. Soft contact lenses (remove; may reinsert 15 minutes after administration). Pregnancy (Cat.C). Nursing mothers: not recommended.
Concomitant oral carbonic anhydrase inhibitors: not recommended. Separate administration of other oph drugs by ≥10 minutes.
Carbonic anhydrase inhibitor (sulfonamide).
Blurred vision, bitter/sour taste, blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia; ocular discharge, discomfort, or itch; keratitis, rhinitis.
Susp—2.5mL, 5mL, 10mL, 15mL
Psychiatry Advisor Articles
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Physicians Spend Nearly 6 Hours on EHR Tasks Per Day
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Buprenorphine, Methadone Combined With CNS Depressants May Lead to SAEs
- Vagus Nerve Stimulation in HIV-Associated Depression
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- Retirement Saving Behavior Associated With Psychological Distress